Bayer Aktiengesellschaft (FRA: BAYN)
Germany
· Delayed Price · Currency is EUR | Market Cap | 18.60B |
| Revenue (ttm) | 46.74B |
| Net Income (ttm) | -880.00M |
| Shares Out | n/a |
| EPS (ttm) | -0.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,226 |
| Open | 19.00 |
| Previous Close | 19.00 |
| Day's Range | 18.80 - 19.12 |
| 52-Week Range | 18.50 - 36.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 5, 2025 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare produc... [Read more]
Financial Performance
Financial StatementsNews
Bayer Eye Drug Shows Positive Results in Late-Stage Trial
Bayer said its eye treatment aflibercept showed positive results in a late-stage trial, including improved vision gains for people suffering from some retinal diseases.
Bayer Eye Drug Shows Positive Results in Late-Stage Trial
Bayer said its eye treatment aflibercept showed positive results in a late-stage trial, including improved vision gains for people suffering from some retinal diseases.
Bayer Partners with America's Grow-A-Row to Aid in the Fight Against Hunger in New Jersey
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced the successful completion of its fall employee engagement campaign with America's Grow-a-Row (AGAR), a New Jersey-based, nonprofit farm where approxima...
Bayer Gets EU Backing for Heart Drug, Easing Patent Concerns
Bayer AG won the backing of European Union regulators for its cardiology drug as the German company fights to offset the looming impact of expiring patents.
Class action members left shocked by decision that ruled in favour of pharmaceutical giant Bayer
The Essure was designed by Bayer as a permanent contraceptive device.
Australian women lose class action against Bayer over birth control device Essure
A Victorian judge has ruled that a group of Australian women's allegations over the Essure birth control device were "far from compelling".
Bayer's Stock Hits 2-Decade Low: Why It Is A Buy Again
Bayer Showcases Growing Radiology Portfolio at RSNA 2024
CHICAGO--(BUSINESS WIRE)--Bayer continues to advance its comprehensive Radiology portfolio with progress in the development pipeline as well as innovations around Artificial Intelligence (AI) and will...
Watermelon Seeds Market Analysis Report 2025-2030, Featuring Bayer CropScience, Vilmorin & Cie, Syngenta, Origene Seeds, GoldSupplier, Tokita Seed Co., Emerald Seed Company & Hazera
Dublin, Nov. 29, 2024 (GLOBE NEWSWIRE) -- The "Watermelon Seeds Market Size, Share & Trends Analysis Report by Type (Raw, Roasted, Dried), Distribution Channel, Region and Segment Forecasts, 2025-2030...
Dhanuka Agritech expands global reach with acquisition of Bayer AG’s active ingredients
This acquisition will allow Dhanuka to manufacture and sell Iprovalicarb and Triadimenol, including their associated brand Melody, across global markets.
Bayer's (BAYRY) Nubeqa sNDA for Prostate Cancer Accepted by FDA
Bayer's (BAYRY) Nubeqa sNDA for Prostate Cancer Accepted by FDA
Bayer Announces ‘Project Enhanced S3' to Enable Companies to Realize Additional Sustainability Value from Carbon Removal Projects
ST. LOUIS--(BUSINESS WIRE)--Bayer announced today an expanded approach to its programs that sequester carbon and reduce emissions for companies along the food value chain through regenerative agricult...
Cytokinetics and Bayer partner to develop for aficamten in Japan
Bayer (BAYRY) and Cytokinetics (CYTK) Collaborate on Japanese HCM Therapy
Bayer (BAYRY) and Cytokinetics (CYTK) Collaborate on Japanese HCM Therapy
Cytokinetics and Bayer Partner to Expand Aficamten's Reach in Japan
Cytokinetics and Bayer Partner to Expand Aficamten's Reach in Japan
Bayer acquires rights to Cytokinetics' heart drug in Japan
Bayer on Tuesday struck a collaboration deal with U.S. biotech firm Cytokinetics to acquire certain rights in Japan to an experimental heart drug, as the German group strengthens its cardiovascular bu...
Bayer Faces Investor Pressure to Accelerate Turnaround Amid Record Lows
Bayer is under growing pressure from investors to expedite its turnaround strategy as CEO Bill Anderson grapples with slumping earnings and a 20-year low in the company’s share price following a stark...
Bayer’s Worst Week in a Year Puts Scale of CEO Task Into Context
As Bayer AG shares head for their worst week in almost a year, the days of 2015 when the German company was valued at more than €120 billion ($127 billion) are an even more distant memory.
Bayer shareholders call on CEO to stem the tide of bad news
Some Bayer investors say CEO Bill Anderson should speed up turnaround efforts, including boosting efficiency and drug development, to restore confidence and revive the company's share price that hit 2...
Bayer to Present New Prespecified Subgroup Analyses from Investigational Phase III FINEARTS-HF Trial in Patients with Heart Failure with LVEF ≥40% at AHA 2024
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will present three new prespecified subgroup analyses from the pivotal Phase III FINEARTS-HF cardiovascular outcomes trial investigating KERENDIA® (finerenone) i...
Bayer AG (BAYRY) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst Challenges
Bayer AG (BAYRY) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst Challenges
Q3 2024 Bayer AG Earnings Call Transcript
Q3 2024 Bayer AG Earnings Call Transcript
Bayer AG (BAYZF) Q3 2024 Earnings Call Transcript
Bayer’s turnaround just got even tougher
Deteriorating market conditions mean chief executive Bill Anderson will have to dig even deeper
Bayer shares fall as pharma giant’s results fail to cheer investors
Bayer’s share price fell on Tuesday, following the company releasing lacklustre third quarter earnings with a warning that the current challenges may also impact next year’s results as well.